Express Mail Label No.: 05153975US
Date of Deposit: February 6, 20

Attorney Docket No. 20363-015 / B

C'd PCT/PTO 06 FEB 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Nadler, et al.

APPLICATION 09/830,400

NUMBER:

•

EXAMINER:

Not Yet Assigned

NUMBER

FILING DATE:

April 25, 2001

ART UNIT:

Not Yet Assigned

FOR:

CANCER IMMUNOTHERAPY AND DIAGNOSIS USING UNIVERSAL TUMOR ASSOCIATED ANTIGENS, SUCH AS THE TELOMERASE CATALYTIC SUBUNIT (HTERT), AND METHODS FOR IDENTIFYING

UNIVERSAL TUMOR ASSOCIATED ANTIGENS

BOX SEQUENCE, P.O. Box 2327

Commissioner for Patents U.S. Patent and Trademark Office Arlington, VA 22202

PRELIMINARY AMENDMENT

Prior to examination of the this application and in response to the Notification of Defective Response mailed on January 18, 2002, please amend the above-identified application as follows:

In the Specification:

Please replace the current sequence listing at the end of the specification with the replacement sequence listing enclosed herewith.

REMARKS

In response to the Notification of Defective Response, Applicants submit herewith a replacement computer readable form (CRF) copy of the "Sequence Listing", and a replacement paper copy of the "Sequence Listing". A statement that the content of the paper and computer readable copies are the same and include no new matter, in compliance with 38 C.F.R. §§ 1.821 –1.825 is also included. The specification has been amended to insert the sequence listing. No new matter is added.

As this response is filed before February 18, 2002, no additional fees are believed due. However, if additional fees are due, the Commissioner is authorized to charge such fees, or credit any overpayments, to Deposit Account No. 50-0311, Reference No. 20363-015.